Ignite Creation Date:
2025-12-25 @ 4:30 AM
Ignite Modification Date:
2026-02-08 @ 10:38 AM
Study NCT ID:
NCT02146118
Status:
UNKNOWN
Last Update Posted:
2014-05-23
First Post:
2014-05-07
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma
Sponsor:
MedicalLogic
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
SLB-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | OTHER | View |